News
News
Date Title
   
January 25, 2011 Oxford BioTherapeutics Out-Licenses Therapeutic Antibody for the Treatment of Solid Cancers
December 09, 2009 Oxford BioTherapeutics Appoints Michael Moore as Chairman
November 11, 2009 Oxford BioTherapeutics Recruits mAb Industry Leaders to Head US Operations
May 18, 2009 Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
December 1, 2008 Oxford Genome Sciences Changes its Name to Oxford BioTherapeutics
February 18, 2008 Oxford Genome Sciences Appoints Professor Elke Jaeger to its Scientific Advisory Board
December 17, 2007 Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
November 21, 2007 Oxford Genome Sciences Appoints Chris Hibberd to its Board of Directors
October 11, 2007 Sir Walter Bodmer Joins Oxford Genome Sciences Scientific Advisory Board
September 18, 2007 Oxford Genome Sciences Announces New Therapeutic Antibody Deal with Medarex
April 18, 2007 Oxford Genome Sciences Recruits Senior Industry Professionals to Drive its Development of Novel Personalised Medicines
March 5, 2007 Oxford Genome Sciences Expands its Scientific Advisory Board
Feb 5, 2007 Oxford Genome Sciences (UK) Ltd secured additional private equity investment round
May 10, 2006 Oxford Genome Sciences and Medarex Sign Therapeutic Antibody Collaboration Agreement in Cancer
April 12, 2006 Oxford Genome Sciences and University of Oxford to develop new clinical biomarkers for colorectal cancer
April 5, 2006 Biosite and Oxford Genome Sciences Announce Collaboration in Colorectal Cancer
June 7, 2005 Oxford Genome Sciences appoints Jeff Warren to the Board of Directors
April 4, 2005 Oxford Genome Sciences closes financing and moves to state-of-the-art proteomics facility
March 14, 2005 Bayer HealthCare Diagnostics and Oxford Genome Sciences Partner in Proteomics-based Evaluation of New Biomarkers for Breast Cancer
 
| Home | About Us | Collaborations | Technologies | News/Events | Contact Us |
© Oxford BioTherapeutics Ltd 2009. All rights reserved.